

**Supplementary File 4 GRADE assessment (Summary of Findings table)**

Table 1. Remdesivir									
№ of studies	Certainty assessment					№ of patients		Effect Value (95% CI)	Certainty
	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Total	Event		
Adverse events									
Single-arm Cohort (3)	Serious <sup>1</sup>	Not serious	Not serious	Serious <sup>2</sup>	None	112	46	37.1% (0.0%, 74.5%)	⊕○○○ VERY LOW
Serious adverse events									
Single-arm Cohort (3)	Serious <sup>1</sup>	Not serious	Not serious	Serious <sup>2</sup>	None	112	21	16.2% (1.8%, 30.5%)	⊕○○○ VERY LOW
Extra-corporeal membrane oxygenation (ECMO) or invasive mechanical ventilation (IMV)									
Single-arm Cohort (3)	Serious <sup>1</sup>	Not serious	Not serious	Serious <sup>2</sup>	None	112	45	37.2% (0%, 76.0%)	⊕○○○ VERY LOW
Mortality									
Single-arm Cohort (3)	Serious <sup>1</sup>	Not serious	Not serious	Serious <sup>2</sup>	None	112	7	5.9% (1.5%, 10.2%)	⊕○○○ VERY LOW

Table 2-1. Glucocorticoids										
№ of studies	Certainty assessment					№ of patients			Effect Value (95% CI)	Certainty
	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Sample	Intervention	Control		
Mortality										
Cohort (1) Case series (1)	Serious <sup>1</sup>	Not serious	Not serious	Serious <sup>2</sup>	None	69	2/40	0/21	2.79 (0.13, 60.87)	⊕○○○ VERY LOW
Mechanical ventilation rate										

Cohort (1) Case series (1)	Serious <sup>1</sup>	Not serious	Not serious	Serious <sup>2</sup>	None	69	14/40	3/21	2.83 (0.78, 10.30)	⊕○○○ VERY LOW
-------------------------------	----------------------	-------------	-------------	----------------------	------	----	-------	------	--------------------	------------------

Table 2-2. Glucocorticoids												
№ of studies	Certainty assessment					№ of patients				Effect Value (95% CI)	Certainty	
	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Sample	Intervention		Control			
							Mean	SD	Mean			SD
Duration of PICU admission												
Cohort (1)	Serious <sup>1</sup>	Not serious	Not serious	Serious <sup>2</sup>	None	69	6.9	8.2	4.9	3.5	2.0 (-0.95, 4.95)	⊕○○○ VERY LOW

Table 3-1. IVIG												
№ of studies	Certainty assessment					№ of patients			Effect Value (95% CI)	Certainty		
	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Sample	Intervention	Control				
Treatment failure												
Cohort (1)	Serious <sup>1</sup>	Not serious	Serious <sup>3</sup>	Not serious	None	96	3/32	24/64	0.25 (0.09, 0.70)	⊕○○○ VERY LOW		
Second-line treatment												
Cohort (1)	Serious <sup>1</sup>	Not serious	Serious <sup>3</sup>	Not serious	None	96	3/32	20/64	0.19 (0.06, 0.61)	⊕○○○ VERY LOW		
Hemodynamic support												
Cohort (1)	Serious <sup>1</sup>	Not serious	Serious <sup>3</sup>	Not serious	None	96	2/32	15/64	0.21 (0.06, 0.76)	⊕○○○ VERY LOW		
LVEF <55%												
Cohort (1)	Serious <sup>1</sup>	Not serious	Serious <sup>3</sup>	Not serious	None	52	2/12	14/40	0.20 (0.06, 0.66)	⊕○○○		

